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Telavancin for Hospital-Acquired Pneumonia: Clinical Response and
28-Day Survival
G. Ralph Corey,a Marin H. Kollef,b Andrew F. Shorr,c Ethan Rubinstein,d Martin E. Stryjewski,e Alan Hopkins,f Steven L. Barrieref

U.S. Food and Drug Administration draft guidance for future antibiotic clinical trials of bacterial nosocomial pneumonia recommends the use of diagnostic criteria according to American Thoracic Society/Infectious Diseases Society of America (ATS/
IDSA) guidelines and the use of a primary endpoint of 28-day all-cause mortality. The effect of applying these guidelines on outcomes of phase III nosocomial pneumonia studies of telavancin was evaluated in a post hoc analysis. ATS/IDSA criteria were
applied in a blind fashion to the original all-treated (AT) group. Clinical cure rates at final follow-up were determined in the refined AT and clinically evaluable (CE) groups (ATS/IDSA-AT and ATS/IDSA-CE, respectively). The exploratory endpoint of 28day survival was evaluated for the ATS/IDSA-AT group. Noninferiority of telavancin versus vancomycin was demonstrated, with
similar cure rates in the ATS/IDSA-AT (59% versus 59%) and ATS/IDSA-CE (83% versus 80%) groups. Cure rates favored telavancin in ATS/IDSA-CE patients where Staphylococcus aureus was the sole pathogen (86% versus 75%). Overall, 28-day survival
rates were similar in the telavancin (76%) and vancomycin (77%) groups but lower in telavancin-treated patients with preexisting moderate-to-severe renal impairment (creatinine clearance [CLCR] of <50 ml/min). Telavancin should be administered to
patients with moderate-to-severe renal impairment only if treatment benefit outweighs the risk or if no suitable alternatives are
available.

H

ospital-acquired pneumonia (HAP) is the second most common nosocomial infection in the United States and is a leading cause of mortality among hospital-acquired infections (1).
The rate of HAP is thought to be between 5 and 10 cases per 1,000
admissions in the United States, with the incidence of ventilatorassociated pneumonia (VAP) being much higher (1). Data for
HAP in Europe are limited, but rates have been estimated to be
approximately 3 cases per 1,000 admissions (2). The mortality rate
for HAP is high, reaching ⬎50% for VAP in some settings (3).
Underlying severe renal impairment has been associated with an
excess risk of hospital mortality. In a study of 471 patients admitted to a medical intensive care unit (ICU), acute renal failure was
shown by multivariate logistic regression analyses to be an independent predictor of mortality (adjusted odds ratio, 3.7; 95% confidence interval [CI], 2.2 to 6.1) (4). In a much larger study of
⬎17,000 patients admitted to an ICU and requiring renal replacement therapy for acute renal failure, the mortality rate was increased 4-fold (5).
In recent years, there has been a substantial increase in the
number cases of pneumonia attributable to multidrug-resistant
pathogens such as methicillin-resistant Staphylococcus aureus
(MRSA), which accounts for between 20 and 40% of all HAP and
VAP cases (6). Shortcomings associated with the limited number
of currently approved treatments for MRSA pneumonia support
the need for new treatment options (7).
Telavancin is a lipoglycopeptide antibacterial agent with a dual
mechanism of action that combines inhibition of cell wall synthesis and disruption of bacterial cell membrane function (8). Telavancin has demonstrated in vitro bactericidal activity against a
range of clinically important Gram-positive bacteria, including
MRSA (9, 10). Telavancin is approved in the United States and
Canada for treatment of adult patients with complicated skin and
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skin structure infections caused by susceptible Gram-positive
pathogens, in the United States for hospital-acquired bacterial
pneumonia/ventilator-associated bacterial pneumonia due to S.
aureus (methicillin-susceptible and -resistant isolates) when other
alternatives are unsuitable, and in Europe for treatment of MRSA
nosocomial pneumonia when other alternatives are unsuitable. (At
the time of submission, the telavancin European marketing authorization for the treatment of nosocomial pneumonia was suspended
pending evidence of a new European Medicines Agency-approved
supplier. Clinigen Healthcare Ltd., Theravance’s commercialization partner for telavancin in Europe, is in the process of seeking
approval of a new manufacturing source.)
In two methodologically identical, randomized ATTAIN
(Assessment of Telavancin for Treatment of Hospital-Acquired
Pneumonia) studies, telavancin was shown to be noninferior to
vancomycin for treatment of patients with HAP due to Grampositive pathogens (11). Telavancin cure rates were higher than
those of vancomycin in clinically evaluable patients with S. aureus
as the sole baseline pathogen isolated and in patients infected with
S. aureus with vancomycin MICs of ⱖ1 g/ml (11). Safety findings were comparable for the two treatment groups, while onstudy mortality rates were ⬍2% higher in the telavancin group
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Telavancin for HAP

TABLE 1 Analysis groupsc
No. (%) of patients
Study 0015

Study 0019

Total

Analysis group

Telavancin

Vancomycin

Telavancin

Vancomycin

Telavancin

Vancomycin

Original
Clinical response and
28-day survival
Clinical response
Clinical response
Clinical response

Original data set, AT
ATS/IDSA-ATa

372 (100)
309 (83)

374 (100)
316 (84)

377 (100)
325 (86)

380 (100)
339 (89)

749 (100)
634 (85)

754 (100)
655 (87)

ATS/IDSA-CEb
ATS/IDSA-AT-GPb
ATS/IDSA-AT-GPOb

116 (38)
157 (51)
115 (37)

148 (47)
155 (49)
113 (36)

147 (45)
194 (60)
110 (34)

149 (44)
188 (55)
111 (33)

263 (41)
351 (55)
225 (35)

297 (45)
343 (52)
224 (34)

a

Percentages are relative to the AT group.
Percentages are relative to the ATS/IDSA-AT group.
c
AT, all treated; ATS, American Thoracic Society; CE, clinically evaluable; CLCR, creatinine clearance; GP, Gram positive; GPO, Gram positive only; IDSA, Infectious Diseases
Society of America.
b

than in the vancomycin group, although this difference was not
statistically significant (11).
Draft U.S. Food and Drug Administration (FDA) guidance
published in 2010 (12) proposed that the inclusion criteria for new
clinical studies of treatments for bacterial HAP be modified to
include specific diagnostic criteria based on management guidelines developed by the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) (1). The ATS/IDSA
guidelines suggest that HAP should be suspected if a patient has
the presence of a new or progressive radiographic infiltrate together with clinical findings suggesting infection, which include
new onset of fever, purulent sputum, and leukocytosis/leukopenia
(1). In addition to recommending the adoption of specific inclusion criteria based on ATS/IDSA guidelines, the draft FDA guidance proposed a primary endpoint of 28-day all-cause mortality,
rather than clinical cure, for trials of treatments for HAP (12).
To evaluate the effect of applying the ATS/IDSA diagnostic
criteria, the revised inclusion criteria from the draft FDA guidance, and the proposed 28-day all-cause mortality endpoint on the
ATTAIN study findings, a post hoc analysis was performed, exploring clinical response and 28-day survival endpoints.
(Most of these analyses were presented at the FDA Anti-Infective Drugs Advisory Committee on 28 November 2012 in support
of the evaluation of the safety and efficacy of telavancin for the
treatment of hospital-acquired bacterial pneumonia/ventilatorassociated bacterial pneumonia due to Gram-positive pathogens.)
MATERIALS AND METHODS
This was a post hoc analysis of data from two identical, randomized, double-blind, comparator-controlled, parallel-group, phase III ATTAIN clinical trials (study 0015, [NCT00107952] and study 0019 [NCT00124020]),
based on supplemental mortality data obtained after study completion.
After FDA affirmation that mortality was viewed as an important efficacy
variable, the sponsor sought additional patient follow-up to day 28 postrandomization to support a day 28 landmark survival endpoint. This supplemental poststudy mortality status follow-up was successful in obtaining complete 28-day follow-up for approximately 95% of all patients. The
remaining 5% were censored at the point of last follow-up prior to day 28.
Details of the study design, methods, and results have been reported
previously (11), without the supplemental mortality data or the description of the ATS/IDSA population. In brief, male and nonpregnant female
patients aged ⱖ18 years were eligible for enrollment if they had pneumonia acquired after 48 h in an inpatient acute- or chronic-care facility or
that developed within 7 days of discharge. This included hospitalized patients with VAP who developed pneumonia de novo after at least 48 h of
mechanical ventilation. Eligible patients were randomized 1:1 to receive
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either 10 mg of telavancin/kg of body weight intravenously every 24 h or 1
g of vancomycin intravenously every 12 h for 7 to 21 days. The vancomycin dosage could be modified per site-specific procedures for body weight
and/or renal function as well as vancomycin trough level monitoring, as
long as the study blind was maintained.
Patients were assessed at baseline and daily throughout study treatment, at the end of therapy, and at the follow-up/test-of-cure (FU/TOC)
visit. FU/TOC assessment was performed 7 to 14 days following the end of
therapy. The prespecified primary endpoint was clinical response at the
FU/TOC visit, defined as follows. Cure was defined as an improvement or
lack of progression of baseline radiographic findings at the end of therapy
(EOT) and resolution of signs and symptoms of pneumonia at FU/TOC.
Failure was defined as persistence or progression of signs and symptoms
or progression of radiological signs of pneumonia at EOT, termination of
study medications due to “lack of efficacy” and initiation within 2 calendar days of a different potentially effective antibiotic, death on or after day
3 attributable to primary infection, or relapsed infection at the TOC visit
after termination of study medications. An indeterminate response was
defined as the inability to determine outcome.
The study protocol for the ATTAIN studies was approved by the institutional review board at each site, and the studies were conducted in
accordance with the Declaration of Helsinki. All patients, or their authorized representatives, provided written informed consent.
Analysis populations. The all-treated (AT) population from the two
ATTAIN studies comprised all patients who received at least one dose
of randomized treatment (11). The ATS/IDSA criteria (presence of
new or progressive radiographic infiltration plus two of the following
clinical features: fever of ⬎38°C, white blood cell count of ⬎10,000 or
⬍4,500/mm3, and purulent secretions [1]) were applied in a blind, programmatic fashion to the AT group from the ATTAIN studies to derive
the refined all-treated population (ATS/IDSA-AT group). Additional
analysis populations were the clinically evaluable (CE) (per-protocol)
subgroup of the ATS/IDSA-AT group (ATS/IDSA-CE group), the ATS/
IDSA-AT-GP group (patients in the ATS/IDSA-AT group with at least
one Gram-positive baseline respiratory pathogen isolated), and the ATS/
IDSA-AT-GPO group (patients in the ATS/IDSA-AT group with only
Gram-positive baseline pathogens isolated, excluding patients with mixed
Gram-positive/Gram-negative infections). The latter two groups are of
scientific and regulatory interest because the outcome addresses efficacy
in patients with targeted telavancin-susceptible organisms.
Statistical analysis. The primary objective of this post hoc analysis was
to assess the clinical response at the FU/TOC visit in patients who met the
ATS/IDSA diagnostic criteria. Differences in cure rates between the telavancin and vancomycin treatment groups were calculated, together with
two-sided 95% CIs. Consistent with the original statistical analysis plan,
aggregated analyses of the ATTAIN trials were performed on the basis that
these two studies had identical protocol designs and were conducted in
approximately the same time frame. Evaluation of clinical response in the
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TABLE 2 Baseline characteristics of the ATS/IDSA-AT groupa
Study 0015

Study 0019

Total

Telavancin
(n ⫽ 309)

Vancomycin
(n ⫽ 316)

Telavancin
(n ⫽ 325)

Vancomycin
(n ⫽ 339)

Telavancin
(n ⫽ 634)

Vancomycin
(n ⫽ 655)

Mean age (yr) ⫾ SD

62 ⫾ 19.1

64 ⫾ 17.1

60 ⫾ 17.8

61 ⫾ 18.1

61 ⫾ 18.4

62 ⫾ 17.7

No. (%) of patients aged ⱖ65 yr

160 (52)

176 (56)

159 (49)

167 (49)

319 (50)

343 (52)

No. (%) of female patients

107 (35)

139 (44)

101 (31)

115 (34)

208 (33)

254 (39)

No. (%) of patients of race
White
African American
Asian
Other

222 (72)
8 (3)
75 (24)
4 (1)

232 (73)
10 (3)
73 (23)
1 (⬍1)

209 (64)
13 (4)
72 (22)
31 (10)

224 (66)
5 (1)
83 (24)
27 (8)

431 (68)
21 (3)
147 (23)
35 (6)

456 (70)
15 (2)
156 (24)
28 (4)

No. (%) of patients with medical history/comorbidity
Diabetes
Congestive heart failure
COPD
Chronic renal failure
Shock
ARDS
Acute lung injury
ICU admission

92 (30)
48 (16)
63 (20)
29 (9)
13 (4)
21 (7)
26 (8)
188 (61)

92 (29)
66 (21)
76 (24)
30 (9)
22 (7)
18 (6)
18 (6)
191 (60)

73 (22)
49 (15)
66 (20)
8 (2)
13 (4)
8 (2)
15 (5)
177 (54)

61 (18)
53 (16)
70 (21)
13 (4)
14 (4)
10 (3)
11 (3)
198 (58)

165 (26)
97 (15)
129 (20)
37 (6)
26 (4)
29 (5)
41 (6)
365 (58)

153 (23)
119 (18)
146 (22)
43 (7)
36 (5)
28 (4)
29 (4)
389 (59)

No. (%) of patients with baseline renal status
Acute renal failure
CLCR ⱕ 50 ml/min
Hemodialysis

38 (12)
117 (38)
9 (3)

30 (9)
124 (39)
8 (3)

26 (8)
91 (28)
3 (⬍1)

28 (8)
91 (27)
5 (1)

64 (10)
208 (33)
12 (2)

58 (9)
215 (33)
13 (2)

No. (%) of patients with use of vasopressor/inotropicsb

26 (8)

41 (13)

20 (6)

41 (12)

46 (7)

82 (13)

Mean APACHE II score ⫾ SD

16 ⫾ 6.6

16 ⫾ 6.4

15 ⫾ 6.3

16 ⫾ 6.7

15 ⫾ 6.5

16 ⫾ 6.6

No. (%) of patients with pneumonia type
VAP
Late VAP (ⱖ4 days on ventilation at diagnosis)

94 (30)
83 (27)

88 (28)
71 (22)

103 (32)
91 (28)

103 (30)
83 (24)

197 (31)
174 (27)

191 (29)
154 (24)

No. (%) of patients with sign of pneumonia
Fever (temp ⬎ 38°C)
WBC count of ⬎10,000 cells/mmc,d
Purulent secretions
Heart rate of ⬎120 beats/min
Respiratory rate of ⬎30 breaths/min
SIRSe

249 (81)
210 (75)
295 (95)
68 (22)
117 (38)
280 (91)

242 (77)
191 (73)
303 (96)
63 (20)
118 (37)
281 (89)

280 (86)
188 (68)
312 (96)
56 (17)
83 (26)
284 (87)

290 (86)
202 (69)
335 (99)
59 (17)
97 (29)
301 (89)

529 (83)
398 (71)
607 (96)
124 (20)
200 (32)
564 (89)

532 (81)
393 (71)
638 (97)
122 (19)
215 (33)
582 (89)

No. (%) of patients with radiological characteristic
Multilobar involvement
Pleural effusion

197 (64)
96 (31)

191 (60)
105 (33)

206 (63)
86 (26)

207 (61)
96 (28)

403 (64)
182 (29)

398 (61)
201 (31)

No. (%) of patients with prior antibiotic use (⬎24 h prior to enrollment)
Any prior antibiotic use
Resistant to prior therapyf
Clinical failure of prior therapyf
Pneumonia despite prior therapyf

151 (49)
26 (17)
74 (49)
77 (51)

179 (57)
36 (20)
70 (39)
93 (52)

179 (55)
45 (25)
109 (61)
86 (48)

195 (58)
51 (26)
111 (57)
88 (45)

330 (52)
71 (22)
183 (55)
163 (49)

374 (57)
87 (23)
181 (48)
181 (48)

c

a
AT, all treated; ARDS, acute respiratory disease syndrome; APACHE II, Acute Physiology and Chronic Health Evaluation II; ATS, American Thoracic Society; CLCR, creatinine
clearance; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IDSA, Infectious Diseases Society of America; PaCO2, partial pressure of carbon dioxide in
arterial blood; VAP, ventilator-associated pneumonia; WBC, white blood cell.
b
Use of dopamine, norepinephrine, dobutamine, epinephrine, or phenylephrine.
c
Components with missing values were converted to 0.
d
Denominator includes only patients with a baseline result.
e
For systemic inflammatory response syndrome (SIRS), patients presented with two or more of the following: temperature of ⬎38°C or ⬍36°C, heart rate of ⬎90 beats/min,
respiration rate of ⬎20 breaths/min or PaCO2 value of ⬍32 mmHg, and leukocyte count of ⬎12,000 mm3, ⬍4,000 mm3, or 10% immature (band) cells.
f
Denominator based on the number of patients who used antibiotics ⬎24 h prior.

current analysis was done according to the protocol’s prespecified noninferiority margin for a difference in clinical response (telavancin-vancomycin) of ⫺20%, as used in the previously successful HAP trials that led to
registration (13).
A secondary objective of this analysis was to assess between-group
differences in survival at 28 days in the ATS/IDSA-AT population. Treat-

2032

aac.asm.org

ment-specific estimates of overall 28-day survival were based on KaplanMeier curves. Differences between treatments and corresponding twosided 95% CIs at day 28 were calculated.
Given the previously noted increased risk of death in critically ill patients in association with severe renal impairment and the reduced efficacy seen with telavancin in patients with preexisting moderate or severe
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TABLE 3 Respiratory pathogens isolated at baseline from patients in the ATS/IDSA-AT group who had a baseline pathogen identifieda
No. (%) of patients
Study 0015

Study 0019

Total

Vancomycin
(n ⫽ 212)

Telavancin
(n ⫽ 263)

Vancomycin
(n ⫽ 259)

Telavancin
(n ⫽ 480)

Vancomycin
(n ⫽ 471)

Respiratory tract pathogen
Isolated from respiratory tract only
Isolated from both respiratory tract
and blood

209 (96)
191 (88)
18 (8)

210 (99)
194 (92)
16 (8)

259 (98)
246 (94)
13 (5)

257 (99)
236 (91)
21 (8)

468 (98)
437 (91)
31 (6)

467 (99)
430 (91)
37 (8)

Gram-positive pathogens
Staphylococcus aureus
MRSA
MSSA
Streptococcus pneumoniae

151 (70)
141 (65)
93 (43)
52 (24)
12 (6)

153 (72)
145 (68)
98 (46)
47 (22)
7 (3)

191 (73)
173 (66)
98 (37)
76 (29)
13 (5)

187 (72)
163 (63)
105 (41)
60 (23)
21 (8)

342 (71)
314 (65)
191 (40)
128 (27)
25 (5)

340 (72)
308 (65)
203 (43)
107 (23)
28 (6)

Gram-negative pathogensb
Pseudomonas aeruginosa
Acinetobacter calcoaceticus
Klebsiella pneumoniae
Escherichia coli
Stenotrophomonas maltophilia

100 (46)
36 (17)
14 (6)
11 (5)
16 (7)
8 (4)

98 (46)
31 (15)
17 (8)
18 (8)
7 (3)
7 (3)

152 (58)
61 (23)
38 (14)
23 (9)
17 (6)
17 (6)

147 (57)
54 (21)
32 (12)
32 (12)
11 (4)
6 (2)

252 (53)
97 (20)
52 (11)
34 (7)
33 (7)
25 (5)

245 (52)
85 (18)
49 (10)
50 (11)
18 (4)
13 (3)

Pathogen isolated from blood only
Gram positive
Gram negative

26 (12)
22 (10)
5 (2)

18 (8)
14 (7)
5 (2)

17 (6)
12 (5)
6 (2)

23 (9)
17 (7)
7 (3)

43 (9)
34 (7)
11 (2)

41 (9)
31 (7)
12 (3)

a

More than one pathogen may be present in any patient. AT, all treated; ATS, American Thoracic Society; IDSA, Infectious Diseases Society of America; MRSA, methicillinresistant S. aureus; MSSA, methicillin-sensitive S. aureus.
b
Recovered from at least 5% of either treatment group across both studies.

renal impairment and complicated skin and skin structure infections, the
survival results, as well as clinical cure results, were stratified by degree of
renal impairment (moderate, with a creatinine clearance [CLCR] value of
30 to ⬍50 ml/min, or severe, with a CLCR value of ⬍30 ml/min). Creatinine clearance was estimated by using the Cockcroft-Gault equation. No
multiplicity adjustments were made for the multiple statistical comparisons reported here.
The enrolled patients in the combined ATS/IDSA-AT group provided
statistical power of 99% (study 0015, 88%; study 0019, 90%) to demonstrate noninferiority of telavancin relative to vancomycin for 28-day survival, with a noninferiority margin of ⫺10%.

RESULTS

Analysis population. The ATS/IDSA-AT group comprised 86%
of the original ATTAIN AT group (1,289/1,503) (Table 1). Approximately 13% of the original ATTAIN AT telavancin group

and 11% of the vancomycin group had chest X-ray findings and
only one clinical feature (primarily purulent sputum); ⬍2% of
patients in each group had only chest X-ray changes.
The baseline demographics and characteristics of the ATS/
IDSA-AT group are shown in Table 2. Frequencies of baseline
comorbidities such as diabetes mellitus, chronic obstructive pulmonary disease, and acute/chronic renal failure were similar between the study and treatment groups. The one notable difference
was that the frequency of vasopressor use at baseline in the vancomycin group was almost twice as high as that in the telavancin
group in both populations (13% versus 7%). Baseline demographics and characteristics were similar to those of the overall
ATTAIN AT population.
The majority of baseline bacterial isolates (91%) were obtained
from respiratory specimens only. The remaining isolates were re-

TABLE 4 Clinical response at test of cure in the ATS/IDSA-AT and ATS/IDSA-CE groups (aggregated analysis stratified by study)a
ATS/IDSA-AT

ATS/IDSA-CE

No. of cured patients/
% difference in telavancin-vancomycin No. of cured patients/
% difference in telavancin-vancomycin
total no. of patients (%) cure rates (95% confidence interval)
total no. of patients (%) cure rates (95% confidence interval)

Study

Treatment

0015

Telavancin
182/309 (59)
Vancomycin 184/316 (58)

1 (⫺7.1, 8.4)

99/116 (85)
117/148 (79)

6 (⫺2.9, 15.5)

0019

Telavancin
194/325 (60)
Vancomycin 202/339 (60)

⬍1 (⫺7.4, 7.6)

119/147 (81)
121/149 (81)

⬎⫺1 (⫺9.2, 8.7)

Total

Telavancin
376/634 (59)
Vancomycin 386/655 (59)

⬍1 (⫺5.0, 5.8)

218/263 (83)
238/297 (80)

3 (⫺3.6, 9.2)

a

AT, all treated; ATS, American Thoracic Society; CE, clinically evaluable; IDSA, Infectious Diseases Society of America.
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Telavancin
(n ⫽ 217)

Pathogen
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⫺15 (⫺30.5, 1.6)b

c

b

Includes patients with monomicrobial Gram-positive infection; patients with a mixed Gram-positive/Gram-negative infection are not included.
Confidence interval using Agresti-Caffo adjustment.
ATS, American Thoracic Society; CE, clinically evaluable; IDSA, Infectious Diseases Society of America; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus.

37/59 (63)
48/61 (79)
2 (⫺25.6, 30.3)b
11/12 (92)
9/10 (90)
12 (⫺0.4, 22.9)b
61/69 (88)
69/90 (77)
12 (⫺5.8, 30.2)b
44/51 (86)
23/31 (74)
11 (⫺1.5, 22.5)
103/120 (86)
95/127 (75)

Treatment

Telavancin
Vancomycin

a

No. of cured
patients/total
no. of
patients (%)

59/69 (86)
72/96 (75)

No. of cured
patients/total
no. of
patients (%)
No. of cured
patients/total
no. of
patients (%)
No. of cured
patients/total
no. of
patients (%)

% difference in
telavancinvancomycin
cure rates (95%
confidence
interval)
% difference in
telavancinvancomycin
cure rates
(95%
confidence
interval)
No. of cured
patients/total
no. of
patients (%)

11 (1.2, 20.8)

No. of cured
patients/total
no. of
patients (%)

% difference in
telavancinvancomycin cure
rates (95%
confidence
interval)
% difference in
telavancinvancomycin
cure rates
(95%
confidence
interval)
% difference in
telavancinvancomycin
cure rates
(95%
confidence
interval)

Streptococcus pneumoniaea
Staphylococcus aureus with
vancomycin MIC ⱖ 1 g/mla
MSSAa
MRSAa
Staphylococcus aureusa

TABLE 5 Clinical response by pathogen at test of cure in the ATS/IDSA-CE group (aggregated analysis not stratified by study)c

% difference in
telavancinvancomycin
cure rates
(95%
confidence
interval)
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covered from respiratory and blood cultures or blood cultures
only. The most common respiratory tract pathogen isolated at
baseline was S. aureus, and the majority of the S. aureus isolates
were MRSA (Table 3). Mixed Gram-positive/Gram-negative infections were identified in 26% (244/951) of ATS/IDSA-AT patients who had a baseline pathogen identified.
Efficacy. For the primary efficacy analysis endpoint of clinical
response at FU/TOC visit, noninferiority was supported in both
the ATS/IDSA-AT and ATS/IDSA-CE analysis groups for studies
0015 and 0019 separately and when the studies were pooled, with
the lower limit of the 95% CIs for all treatment group differences
exceeding the prespecified ⫺20% margin and also above ⫺10%
(Table 4). Cure rates were 59% (376/634) and 59% (386/655) for
telavancin and vancomycin, respectively, in the ATS/IDSA-AT
group and 83% (218/263) and 80% (238/297), respectively, in the
ATS/IDSA-CE group (both studies combined) (Table 4).
In patients with only S. aureus isolated at baseline, cure rates
observed for telavancin were higher than those observed for vancomycin in the ATS/IDSA-CE group (86% versus 75%; 95% CI
for the difference, 1.2% to 20.8%). The higher cure rates for telavancin were consistent in patients with MRSA, methicillin-susceptible S. aureus (MSSA), or S. aureus strains with MICs of vancomycin of ⱖ1 g/ml, although these differences were not
statistically significant owing to smaller sample sizes (Table 5).
Cure rates were lower (although not statistically significantly so)
in patients with mixed infections (Gram-positive and Gram-negative pathogens) in the telavancin group.
When the clinical cure rate was assessed according to baseline
CLCR, numerically lower cure rates with telavancin were observed
in patients with baseline CLCR values of ⬍50 ml/min. Of note,
regardless of renal function, cure rates in the telavancin group
were higher in patients with only Gram-positive pathogens isolated at baseline than in the overall AT population (Table 6).
Analysis of survival at 28 days. The analysis of survival at 28
days revealed similar survival rates between the two treatment
groups across the two studies (Fig. 1). Lower survival rates (Kaplan-Meier estimates) were observed for patients treated with
telavancin than for patients treated with vancomycin who had
moderate-to-severe (CLCR, ⬍50 ml/min) (59% and 70%, respectively) or severe (CLCR, ⬍30 ml/min) (47% and 61%, respectively) renal insufficiency (Fig. 2). For patients with CLCR values of
ⱖ50 ml/min, the survival rate at 28 days for the telavancin group
was similar to that for the vancomycin group (84% and 81%,
respectively).
Safety. The overall safety findings of the ATTAIN trials were
described in detail previously (11). In the ATS/IDSA-AT population, 82% (519/636) of the telavancin group and 81% (532/653) of
the vancomycin group experienced at least one adverse event
(AE), and 30% (193/636) of the telavancin group and 27% (176/
653) of the vancomycin group experienced a serious AE. Discontinuations due to AEs were reported for 8% (51/636) of telavancin-treated patients and 5% (34/653) of vancomycin-treated
patients. The incidences of individual AEs were similar in the two
treatment groups, with diarrhea, anemia, hypokalemia, and constipation being the most common (⬎5%) in both treatment
groups. Renal AEs (failure, impairment, insufficiency, or elevations in serum creatinine levels) occurred in 9% (59/636) and 8%
(51/653) of telavancin- and vancomycin-treated patients, respectively. Among patients with normal baseline renal function, potentially clinically significant increases in serum creatinine levels

Mixed infection
(Gram positive ⫹ Gram negative)

Corey et al.
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TABLE 6 Clinical cure rate by baseline creatinine clearance (aggregated analysis not stratified by study)a
ATS/IDSA-AT

CLCR
(ml/min) Treatment

ATS/IDSA-AT-GP

% difference in
No. of cured
telavancin-vancomycin No. of cured
patients/total no. cure rates (95%
patients/total no.
of patients (%)
confidence interval)
of patients (%)

ATS/IDSA-AT-GPO
% difference in
telavancin-vancomycin No. of cured
cure rates (95%
patients/total no.
confidence interval)
of patients (%)

% difference in
telavancin-vancomycin
cure rates (95%
confidence interval)

Telavancin 32/83 (39)
Vancomycin 39/83 (47)

⫺8 (⫺23.4, 6.6)

15/37 (41)
22/43 (51)

⫺11 (⫺32.4, 11.1)

10/23 (43)
16/32 (50)

⫺7 (⫺33.2, 20.1)

ⱖ30

Telavancin 344/551 (62)
Vancomycin 347/572 (61)

2 (⫺3.9, 7.5)

189/314 (60)
183/300 (61)

⫺1 (⫺8.5, 6.9)

142/202 (70)
120/192 (63)

8 (⫺1.5, 17.1)

⬍50

Telavancin 92/197 (47)
Vancomycin 114/209 (55)

⫺8 (⫺17.5, 1.9)

45/95 (47)
59/111 (53)

⫺6 (⫺19.5, 7.9)

38/68 (56)
44/82 (54)

2 (⫺13.8, 18.2)

ⱖ50

Telavancin 284/437 (65)
Vancomycin 272/446 (61)

4 (⫺2.4, 10.4)

159/256 (62)
146/232 (63)

⫺1 (⫺9.4, 7.8)

114/157 (73)
92/142 (65)

8 (⫺2.7, 18.3)

a

AT, all treated; ATS, American Thoracic Society; CE, clinically evaluable; CLCR, creatinine clearance; GP, Gram positive; GPO, Gram positive only; IDSA, Infectious Diseases Society of
America.

(maximum value of ⱖ1.33 mg/dl and at least a 50% increase from
baseline) occurred in 14% (71/505) of the telavancin group and in
10% (50/523) of the vancomycin group.
DISCUSSION

The ATTAIN studies were two methodologically identical, randomized, phase III studies that demonstrated the noninferiority of
telavancin relative to vancomycin for the treatment of HAP, including VAP, due to Gram-positive organisms on the basis of
clinical response (11). In this post hoc analysis, the ATS/IDSA HAP
diagnostic criteria were applied to the AT study group from the
ATTAIN studies to evaluate the potential effect on clinical outcomes. The results of this analysis support the noninferiority of
telavancin relative to vancomycin with regard to clinical response
when the ATS/IDSA diagnostic criteria were applied. Further-

more, our analysis suggests that patients with infections due solely
to S. aureus (MRSA or MSSA) treated with telavancin had higher
cure rates than such patients treated with vancomycin. This may
be related to a better in vitro activity of telavancin against S. aureus,
including strains with higher vancomycin MICs. Given these findings, it would be appropriate to consider telavancin as a therapeutic option for the management of pneumonia due to S. aureus
(MRSA and MSSA) in patients without moderately to severely
compromised renal function and as potentially useful in patients
with compromised renal function if no other suitable alternatives
are available.
Antibiotic resistance poses a significant risk to public health.
The incidence of MRSA continues to increase (6), while infections
due to vancomycin-intermediate S. aureus, heteroresistant vancomycin-intermediate S. aureus, and vancomycin-resistant S. aureus

FIG 1 Kaplan-Meier survival curves showing 28-day survival in study 0015 (A), study 0019 (B), and the aggregate (C) for the ATS/IDSA-AT population. CI,
confidence interval; S, survival rate; TLV, telavancin; VAN, vancomycin.
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⬍30
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of ⬍30 ml/min (A), ⱖ30 ml/min (B), ⬍50 ml/min (C), and ⱖ50 ml/min (D). CI, confidence interval; CLCR, creatinine clearance; S, survival rate; TLV, telavancin;
VAN, vancomycin.

have also emerged (14, 15). The previously reported results of the
ATTAIN studies suggested that telavancin was potentially more
effective than vancomycin in patients infected with S. aureus
strains with vancomycin MICs of ⱖ1 g/ml (11). Although not
statistically significant (owing to a smaller sample size of patients),
the same trend was observed in this analysis, with a similarly large
and clinically meaningful difference in cure rates between the
treatment groups. Therefore, telavancin may be a reasonable empirical therapeutic option in centers with high rates of S. aureus
with elevated vancomycin MICs.
Analysis of 28-day all-cause survival showed similar survival
rates between telavancin-treated and vancomycin-treated patients, although our analysis did highlight lower survival rates in
patients with moderate or severe renal dysfunction who received
telavancin than in those who received vancomycin. The mechanism of this increased risk is unclear, and interpretation of mortality as an endpoint of HAP is confounded by nonattributable
mortality, which may be the result of variables that are unrelated
to pneumonia. The ATTAIN studies evaluated clinical outcome as
the primary endpoint and thus excluded only cases where death
was expected within 7 days. However, despite appropriate dosage
adjustments for renal function, nephrotoxicity due to telavancin
in patients with preexisting renal impairment cannot be ruled out
as a contributing factor. The use of telavancin in patients with
CLCR values of ⬍50 ml/min should therefore be considered only
when the benefits outweigh any potential risks or if other alternatives are not suitable. Monitoring of renal function in these patients should be performed routinely (11).
Limitations of this study include the fact that it is a post hoc
analysis. The ATS/IDSA criteria were, however, applied programmatically in a blind fashion. Using these criteria, it was possible to
ensure that the patients included in the analysis were those most
likely to have pneumonia. However, each of the analyses used a
subgroup of the original ATTAIN study population, with decreasing numbers of patients in each analysis group potentially reduc-
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ing the power of the analysis to demonstrate noninferiority. That
said, the all-treated group retained a sufficient sample size to ensure adequate statistical power. The 28-day mortality endpoint,
while potentially confounded by nonattributable mortality, is an
objective outcome measure and, in these studies, identified a
group of patients for whom caution should be taken when considering the use of telavancin.
Conclusions. The results of this reanalysis of the ATTAIN patient population suggest that telavancin is noninferior to vancomycin for clinical cure of HAP, including VAP, due Gram-positive
organisms when the ATS/IDSA diagnostic criteria are applied. In
this analysis, cure rates against S. aureus were numerically higher
than those with vancomycin for both MRSA and MSSA infections,
suggesting that telavancin is an effective therapy for HAP due to S.
aureus, including cases caused by S. aureus strains with high or
unknown vancomycin MICs. The use of telavancin in patients
with preexisting moderate-to-severe renal function should be
considered only if the benefits of treatment outweigh the risks or
in the absence of other suitable alternatives.
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